|本期目录/Table of Contents|

[1]顾海滨,刘山明.老年2型糖尿病使用门冬胰岛素30注射液联合吡格列酮治疗临床分析[J].慢性病学杂志,2016,(08):868-871.
　GU Hai-bin,LIU Shan-ming.Effects of insulin aspart 30 combined with pioglitazone on senior patients wih type 2 diabetes mellitus[J].,2016,(08):868-871.
点击复制

老年2型糖尿病使用门冬胰岛素30注射液联合吡格列酮治疗临床分析(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2016年08期
页码:
868-871
栏目:
论著
出版日期:
2016-09-27

文章信息/Info

Title:
Effects of insulin aspart 30 combined with pioglitazone on senior patients wih type 2 diabetes mellitus
作者:
顾海滨; 刘山明
厦门市第三医院，福建厦门360011
Author(s):
GU Hai-bin;  LIU Shan-ming
Third Hospital of Xiamen, Xiamen, Fujian 360011, China Corresponding author: GU Hai-bin, E-mail: guhaibin0817@163.com
关键词:
2 型糖尿病; 门冬胰岛素; 吡格列酮
Keywords:
Type 2 diabetes mellitus;  Insulin as part 30;  Pioglitazone
分类号:
R587.2
DOI:
-
摘要:
目的探讨门冬胰岛素30 注射液联合吡格列酮治疗老年2 型糖尿病的疗效。方法选取2010 年 10 月—2012 年10 月厦门市第三医院内分泌科门诊治疗40 例老年2 型糖尿病患者，均单独应用胰岛素治疗 3 个月以上，所有患者随机分为观察组和对照组，每组20 例，观察组采用门冬胰岛素30 注射液联合吡格列 酮治疗，对照组仅给予门冬胰岛素30 注射液治疗。治疗3 个月后检测并比较两组患者治疗前后空腹血糖 （FPG）、餐后2 小时血糖（2 hPG）、糖化血红蛋白(HbA1c)、丙氨酸氨基转移酶（ALT）、天冬氨酸转氨酶 （AST）、尿素氮（BUN）、肌酐（Cr）、甘油三酯（TG）、血红蛋白（Hb） 及胰岛素用量等项目。结果 观察组治疗后FPG、2 hPG、HbA1c、TG 及胰岛素用量均明显低于对照组(P<0.01)。结论门冬胰岛素 30 注射液联合吡格列酮治疗可有效控制老年2 型糖尿病患者血糖和血脂水平，减少了胰岛素用量。
Abstract:
Objective To investigate the effect of pioglitazone combined with insulin aspart 30 on patients with type 2 diabetes mellitus. Methods Totally 40 cases of type 2 diabetes mellitus who were from endocrinology department in the third hospital of Xiamen during october 2010 to October 2012 were enrolled and randomly divided into control group with insulin aspart 30 treatment (20 cases) and observation group which was treated by insulin aspart 30 combined with pioglitazone for three months (20 cases). We detected FPG, 2 hPG, HbA1c, ALT, AST, BUN, Cr, TG, Hb and insulin dosage before treatment and after treatment for 3 months, and compared them between the two groups. Results The FPG, 2 hPG, HbA1c, TG and insulin dosage in observation group were lower than those in control group after treatment (all P<0.05). Conclusions Insulin aspart 30 combined with pioglitazone can control the blood glucose and blood lipid level, decrease the insulin dosage in elddly patients with type 2 diabetes mellitus.

参考文献/References:

[1] J?nsson B. CODE- 2 Advisory Board. Revealing the cost of Type II diabetes in Europe [J]. Diabetologia, 2002,45(7):5- 12.
[2] Rosenblum M, Kane M. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with type 2 diabetes mellitus [J]. J M Care Pharm, 2003,9(4):309-316.
[3] 翁建平,李延兵,许雯,等. 短期持续胰岛素输注治疗对初诊2 型糖尿病患者胰岛细胞功能的影响[J]. 中国糖尿病杂志, 2003, 11(1):10-15.
[4] 叶新华,杜云峰,高剑波,等. 短期诺和锐强化治疗对初诊2 型 糖尿病患者胰岛细胞功能的影响[J] . 中华糖尿病杂志,2005, 13 (2) : 114-117.
[5] 李浩华,胡敏凤,周懿明,等. 益肾汤治疗2 型糖尿病50 例[J]. 中国中医药现代远程教育,2010,8(10):98.
[6] 康征. 吡格列酮在治疗高血压合并2 型糖尿病中的价值分析 [J]. 中国中医药现代远程教育,2009,7(10):52.
[7] 窦念涛. 盐酸吡格列酮对2 型糖尿病患者的长期疗效及安全性 探讨[J]. 安徽医药,2008,12(8):742.
[8] Liebl A, Jones S, Benroubi M, et al. Clinical outcomes after insulin initiation in patients with type 2 diabetes: 6-month data from the INSTIGATE observational study in five European countries [J]. Curr Med Res Opin, 2011,27(5):887-895.
[9] 李永峰,张慧. 盐酸吡格列酮对2 型糖尿病患者的长期疗效与 安全性分析[J]. 中国现代药物应用,2008,2(9):41-43.
[10] 雷永珍. 胰岛素与吡格列酮治疗初诊2 型糖尿病的疗效观察 [J]. 实用糖尿病杂志,2007,3(4):43-44.
[11] Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient- centered ap? proach. Position statement of the American Diabetes Associa? tion (ADA) and the European Association for the Study of Dia? betes (EASD) [J]. Diabetologia, 2012,35(6):1364-1379.
[12] Dormandy JA, Charbonnel B, Eekland DJ, et al. Secondary Prevention of macro vascular events in Patients with type 2 di? abetes in the PRO active Study (PROS pective pioglitazone clinical trial in macrovaseular events):a randomized controlled trial [J]. Lancet, 2005,366(9493):1279-1289.
[13] 程强,江牡丹. 短期胰岛素强化治疗对2 型糖尿病血脂、血糖 的影响[J]. 海南医学, 2010,21(6): 59-60.
[14] Jones S, Benroubi M, Castell C, et al. Characteristics of pa? tients with type 2 diabetes mellitus initiating insulin therapy: baseline data from the instigate study[J]. Curr Med Res Opin, 2009,25(3):691-700.

备注/Memo

备注/Memo:
作者简介：顾海滨，大学本科，副主任药师，研究方向： 医院药学 通信作者：顾海滨，E-mail: guhaibin0817@163.com
更新日期/Last Update: 2016-09-27